GuiDeCode
Calcs › ◻ Dermatology

Scoring Mastocytosis (SCORMA) Index

Quantifies severity of cutaneous mastocytosis by combining skin lesion morphology and area with systemic symptom burden

Calculator

Loading calculator…

Why use it

Mastocytosis severity is difficult to capture with single-domain measures — skin lesion extent alone does not reflect the burden of systemic symptoms (flushing, anaphylaxis, gastrointestinal distress), while symptom scores alone do not capture the cutaneous disease activity. The SCORMA Index combines both, enabling a comprehensive assessment that tracks response to treatment and correlates with quality of life in CM patients. It is increasingly used as a primary or secondary endpoint in CM clinical trials and forms part of standardized assessment in European mastocytosis reference centers.

About

The SCORMA (SCORing MAstocytosis) Index is a validated composite scoring tool designed to quantify the severity of cutaneous mastocytosis (CM) — primarily urticaria pigmentosa (maculopapular cutaneous mastocytosis) and other forms of CM — by integrating skin lesion characteristics with the burden of systemic mast cell mediator-related symptoms. Developed by Heide, Lange, and colleagues and published in the British Journal of Dermatology in 2009, the SCORMA Index was adapted from the SCORAD system for atopic dermatitis. The score has two major components: (A) a Skin Score calculated as (morphology grade × area grade)/2, producing a value between 0 and 4.5; and (B) a Symptom Score derived from the sum of four symptom domains — pruritus, flushing/flush attacks, gastrointestinal symptoms, and anaphylaxis/syncope — each rated 0–3, yielding a symptom sum of 0–12. The Total SCORMA = Skin Score (0–4.5) + Symptom Score (0–12), with a total range of 0 to 16.5. Additional dermographism can also be incorporated in some versions but is not part of the standard SCORMA total. Higher scores indicate more severe disease. The SCORMA has been validated as sensitive to treatment-related change, making it a useful endpoint in clinical trials of KIT inhibitors (midostaurin, avapritinib), antihistamines, and phototherapy.

When to use

  • Baseline severity assessment in patients with cutaneous mastocytosis (urticaria pigmentosa, diffuse cutaneous mastocytosis, mastocytoma)
  • Serial monitoring of treatment response to antihistamines (H1 + H2), phototherapy (PUVA/NB-UVB), or KIT inhibitors (midostaurin, avapritinib)
  • Clinical trial endpoint for mastocytosis therapies
  • Assessment of symptom burden for patient counseling and treatment escalation decisions
  • Tracking disease severity in pediatric mastocytosis (accounts for mast cell-related symptoms which predominate in children)
  • NOT validated as a standalone tool for systemic mastocytosis (SM) — use additional WHO criteria and serum tryptase, bone marrow biopsy, and D816V mutation testing for SM staging

Formula

SCORMA Index = Skin Score (A) + Symptom Score (B) A — SKIN SCORE = (Morphology × Area) ÷ 2 Morphology Grade (0–3): 0 = No lesions 1 = Macules only (flat spots) 2 = Maculopapular or nodular lesions (raised) 3 = Plaque-type, bullous, or telangiectatic lesions Area Grade (0–3): 0 = 0% body surface area 1 = 1–25% BSA 2 = 26–50% BSA 3 = >50% BSA Skin Score range: 0 – 4.5 B — SYMPTOM SCORE = Sum of 4 symptoms (each 0–3) Pruritus: 0=None | 1=Mild | 2=Moderate | 3=Severe Flushing: 0=None | 1=Mild/rare | 2=Moderate | 3=Frequent/severe GI symptoms: 0=None | 1=Mild | 2=Moderate | 3=Severe Anaphylaxis/syncope: 0=None | 1=1 episode | 2=2-3 episodes | 3=≥4 episodes or recurrent syncope Symptom Score range: 0 – 12 TOTAL SCORMA = A + B (range 0 – 16.5) 0–5: Mild disease 6–11: Moderate disease 12–16.5: Severe disease

Pearls & pitfalls

  • The skin score is calculated as (morphology × area)/2 — the division by 2 prevents the skin component from overwhelming the symptom component.
  • Flushing and anaphylaxis/syncope in the symptom score are the most clinically significant items — any score ≥2 for anaphylaxis (≥1 episode of syncope) should prompt immediate epinephrine auto-injector prescription regardless of SCORMA total.
  • Serum baseline tryptase (normal <11.4 ng/mL) is an important biomarker complementary to SCORMA — tryptase >20 ng/mL with CM features suggests possible systemic mastocytosis and triggers bone marrow evaluation.
  • In pediatric mastocytosis (typically urticaria pigmentosa or mastocytoma), the SCORMA symptom burden may be underestimated if parents report symptoms rather than the child directly — use age-appropriate assessment.
  • The Darier sign (wheal and flare response to rubbing a lesion) confirms active mast cell infiltration and is a hallmark of CM — include in the broader physical examination alongside SCORMA.
  • Dermographism, while not part of the standard SCORMA total, reflects mast cell hyperreactivity and should be noted clinically — it is recorded separately in some versions of the tool.
  • Triggers to document alongside SCORMA: temperature extremes (hot baths, cold exposure), physical friction, alcohol, NSAIDs, opioids, insect venom, contrast media, and emotional stress.
  • In systemic mastocytosis (SM), the SCORMA reflects CUTANEOUS component only — overall SM severity is governed by the ISM/SSM/ASM/MCL classification, ECNM score, and end-organ involvement.
  • Most pediatric CM spontaneously regresses by adolescence — serial SCORMA documentation helps track this natural history and avoids unnecessary treatment escalation.

Next steps

SCORMA 0–5 (Mild): Basic antihistamine therapy. H1 antihistamine (cetirizine, loratadine) ± H2 antihistamine (ranitidine/famotidine). Avoidance triggers. Monitor for anaphylaxis. SCORMA 6–11 (Moderate): Optimize antihistamine therapy — higher-dose or sedating H1 antihistamines (chlorphenamine). Consider phototherapy (PUVA or NB-UVB for widespread lesions). Epinephrine auto-injector prescription if any history of anaphylaxis. Referral to mastocytosis center. SCORMA 12–16.5 (Severe): Specialist mastocytosis center referral. Consider KIT inhibitor therapy (midostaurin approved for advanced SM; avapritinib for SM with D816V mutation). Cladribine for severe refractory symptoms. Systemic mastocytosis evaluation (bone marrow biopsy, serum tryptase). Comprehensive trigger avoidance education.

Evidence

Heide R et al. Mastocytosis in children: a protocol for management. Pediatr Dermatol. 2008. Lange M et al. A new scoring index for the grading of severity of urticaria pigmentosa in adult patients. Dermatology. 2009;218(3):278-284. PMID:19122441. Validated in European CM cohorts. Correlation with quality of life (DLQI) r=0.72. Sensitivity to change demonstrated in midostaurin and avapritinib trials. Siebenhaar F et al. European Competence Network on Mastocytosis (ECNM) recommendations for mastocytosis assessment. Allergy. 2023.

References

  1. Lange M et al. A new scoring index for the grading of severity of urticaria pigmentosa in adult patients. Dermatology. 2009;218(3):278-284. — link
  2. Heide R et al. Urticaria pigmentosa: clinical presentation, disease duration and prognosis in 173 paediatric patients and comparison with 79 adults. Br J Dermatol. 2008;158(4):840-846. — link
  3. Valent P et al. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420-1427. — link
  4. Siebenhaar F et al. European Competence Network on Mastocytosis (ECNM): achievements, current priorities and future goals. Allergy. 2019;74(7):1287-1300. — link